Pulmatrix
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 22
- Market Cap
- $7.5M
- Website
- http://www.pulmatrix.com
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05667662
- Locations
- 🇺🇸
University of Alabama Medical Center at Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
🇺🇸Jonathan Corren, MD, Santa Monica, California, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults
- Conditions
- Healthy
- Interventions
- Other: Matching Placebo for D.H.E 45Other: Matching Placebo for PUR3100
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05351086
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
A Phase 1b Study of PUR1800 in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo ComparatorDrug: PUR1800 250 ugDrug: PUR1800 500 ug
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04759807
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd., Manchester, Wythenshawe, United Kingdom
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03960606
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Integrity Clinical Research Center Inc., Hialeah, Florida, United States
Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03479411
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧Quotient Sciences, Nottingham, United Kingdom
A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02671825
- Locations
- 🇧🇬
Tokuda Hospital, Sofia, Bulgaria
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
- Conditions
- Postoperative Wound Infection-deepPost Operative Wound Infection
- Interventions
- Drug: Sterile saline for irrigation
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02280395
- Locations
- 🇺🇸
University of South Alabama Medical Center, Mobile, Alabama, United States
🇺🇸University of California, San Diego, Thornton Hospital, La Jolla, California, United States
🇺🇸BJJS, Corp., Memorial Hermann Memorial Medical Center, Houston, Texas, United States
21 Day Cumulative Skin Irritation of RUT058-60
- Conditions
- Irritation/Irritant
- Interventions
- Drug: 0.9% Physiological Saline, USPDrug: Hypochlorous acid solution 106 mg/LDrug: 0.1% (w/v) Sodium Lauryl Sulfate
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02198963
- Locations
- 🇺🇸
BioScience Laboratories, Inc., Butte, Montana, United States
A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01921712
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧Quotient Clinical, Nottingham, United Kingdom
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01690949
- Locations
- 🇩🇪
Fraunhofer Institut fur Toxicologie und Experimentelle Medicine (ITEM), Hannover, Germany